Virtici

What Virtici does

Virtici is a Seattle-based, privately held biotechnology company founded in 2011 that develops therapeutic products and builds life science companies. The company's stated focus is on novel peptide therapeutics, with its currently disclosed lead program targeting periodontitis, an inflammatory gum disease that affects periodontal tissues. Operationally, Virtici is a small organization of 1–10 employees led by President & CEO Neil Fanger, and is classified within the Healthcare/Medical customer segment.

Its disclosed technology activity centers on a novel peptide treatment for periodontitis. The company's public-facing web presence is limited (the virtici.com domain returns a placeholder page), and no named products, platforms, patents, or technology stack details were identified in the available source material beyond the indication of proprietary peptide science. Virtici has secured Phase 2 SBIR (Small Business Innovation Research) funding from the U.S. National Institutes of Health in 2025 to advance the periodontitis peptide therapy.

The business model is consistent with an early-stage, preclinical-to-clinical R&D-stage biotech: revenue is not publicly disclosed, pricing is not publicly disclosed, and there are no named commercial customers. Capital is sourced from non-dilutive federal SBIR grant funding tied to milestone-based program progression, rather than from product sales or licensing revenue. Given the absence of commercial products, named customers, or disclosed contract values, the company is best characterized as pre-revenue and reliant on grant and (presumably) future equity or partnership capital to advance its therapeutic pipeline.

Name

Virtici

Website

https://virtici.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

Virtici is a Seattle-based private biotechnology company developing novel peptide therapeutics, with a current lead program targeting periodontitis and supported by NIH SBIR Phase 2 funding.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Research & Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

akta.pro secondary industries

Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Peptide therapeutics
• Periodontal disease treatment
• Biopharmaceutical R&D
• Life science ventures
• Therapeutic development

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Core offering

Virtici develops novel peptide therapeutics targeting inflammatory diseases, with its current lead program being a peptide-based treatment for periodontitis supported by NIH SBIR Phase 2 funding awarded in 2025. The company combines therapeutic R&D expertise with capabilities for building and advancing life science ventures.

Product overview

Virtici is a biotechnology company developing novel peptide treatments for medical conditions. Based on available source data, the company is focused on advancing a peptide therapy for periodontitis, supported by NIH SBIR funding. No specific named products, platforms, or modules were identified in the provided source data.

Differentiator

Problem solved

Functional benefit

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves3 records

Expansion highlights3 records

Broad incumbents

• Zealand Pharma: Established peptide therapeutics company with multiple clinical-stage assets across metabolic and inflammatory indications. Broad incumbent — same peptide modality at larger scale, demonstrating the platform category's commercial potential.
• Colgate-Palmolive: Global oral-care leader with extensive periodontal product portfolio (e.g., Colgate PerioGard, prescription dentifrices). Broad incumbent — sets the competitive standard for any novel periodontal therapy targeting consumer and dental channels.
• Galderma: Global dermatology and oral-care-focused pharmaceutical company. Broad incumbent — overlapping interest in oral inflammatory diseases and ability to commercialize a periodontal therapy at scale.
• Sunstar: Global oral-care company (GUM brand) with research programs and products targeting periodontal disease. Broad incumbent — comparable focus on periodontal therapeutics within a larger oral-care portfolio.
• Dentaid: International oral-care company producing periodontal and preventive dentistry products. Broad incumbent — directly competes in the periodontitis management space with established consumer and professional channels.

Direct peers

• PepGen: Biotech developing peptide-conjugated oligonucleotides for neuromuscular and inflammatory diseases. Direct peer — small-cap peptide-platform biotech with comparable development-stage and capitalization profile.
• Palatin Technologies: Small-cap biotech developing peptide therapeutics for inflammatory and metabolic diseases. Direct peer — matches the peptide therapeutic modality and inflammation focus at a comparable small-team stage.
• Crinetics Pharmaceuticals: Clinical-stage company developing peptide therapeutics, primarily targeting endocrine and inflammatory conditions. Direct peer — same therapeutic peptide platform model applied to inflammation-related indications.
• Amyndas Pharmaceuticals: Clinical-stage biotech developing complement-targeting peptides (e.g., AMY-101) for inflammatory diseases including periodontitis. Direct peer — same modality (peptide therapeutic), same indication, same mechanism class (host-modulation peptide).

Emerging players

• BioGaia: Probiotics company with an oral-health franchise (e.g., BioGaia Prodentis) targeting gum inflammation and periodontal disease. Emerging player — adjacent host-modulation approach to periodontal health.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Virtici